English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Carbapenem-resistant Enterobacteriaceae (CRE) are one of the most notorious aetiological agents causing nosocomial infection in hospitals across many countries (Cornaglia et al., 2011; Queenan & Bush, 2007). The widespread dissemination of CRE has led to an increase in its prevalence in the USA (CDC, 2012; Endimiani et al., 2009). Carbapenemases are b-lactamases with a major role in bacterial drug resistance. They hydrolyze antibiotics commonly used in clinical settings, including carbapenems, penicillins, cephalosporins and monobactams (Queenan & Bush, 2007). Bacteria containing these enzymes can cause serious infections and complicate treatment plans for patients. The IMP-type enzymes, a subclass under class B carbapenemases, were first identified in Japan in 1991 (Osano et al., 1994). Since then, more than 50 IMP-type b-lactamases have been described (Cornaglia et al., 2011).

New variant of an imipenemase, IMP-32, in Klebsiella pneumoniae from a fatal case of a Thai patient